Clinical epidemiological characterization of patients with pancreas cancer in a general surgery service
Keywords:
pancreas cancer, comorbidities, diagnosis, epidemiology.Abstract
Introduction: The pancreas cancer constitutes one of the neoplasms with worse prognosis due to its late diagnosis.
Objective: To characterize patients with pancreas cancer according to clinical epidemiological variables and complementary exams.
Methods: An observational, descriptive and cross-sectional study of 70 patients with pancreas cancer was carried out, who were discharged from the General Surgery Service of Saturnino Lora Teaching Provincial Hospital in Santiago de Cuba during 2016-2020. The variables studied were: age, sex, risk factors, associated diseases, signs and symptoms and complementary exams.
Results: There was a prevalence of the male sex (54.2 %), the 51-70 age group, the ingestion of fatty foods and nicotine addiction and alcoholism as risk factors, the chronic alcoholism, diabetes mellitus and hypertension as more common associated diseases, as well as the general syndrome, jaundice and coluria among the most frequent signs and symptoms. On the other hand, according to the imaging studies, most of those affected were diagnosed by means of computerized axial tomography and abdominal echography (94.3 and 70.0 %, respectively).
Conclusions: The multiscan computerized axial tomography is the image technique of election recommended by the guides of international consent. The radiographic report is the key for later decisions making but there are circumstances of the patient that can affect them, such as age, risk factors, signs and symptoms and comorbidity, among others.
Downloads
References
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020 [citado 24/02/2020];70:7-30. Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21590
3. Zelaya Rodríguez GE. Morbimortalidad perioperatoria y principales complicaciones de los pacientes operados de cirugía de Whipple por cáncer de páncreas y neoplasias periampulares en el servicio de cirugía oncológica en el HRCG en el período de enero 2017 a diciembre 2020 [Tesis en opción al título de Especialista en Cirugía General]. Managua: Universidad Nacional Autónoma de Nicaragua; 2021.
4. Kohan G, Moro M, Pasqua A, Volpacchio M, Marcaccio F, Kujaruk M, et al. Recomendaciones para el diagnóstico y tratamiento del adenocarcinoma ductal de páncreas. Club del Páncreas de la República Argentina. Acta Gastroenterol Latinoam. 2020 [citado 20/06/2022];50(2). Disponible en: https://www.redalyc.org/journal/1993/199368570001/html/
5. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019 [citado 24/02/2020];10(1):10-27. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396775/
6. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 [citado 24/02/2020];24(43):4846-61. Disponible en: https://doi.org/10.3748/wjg.v24.i43.4846.
7. Madrigal Ureña A, García Chaves D. Cáncer de páncreas: alteraciones genéticas, cambios morfológicos y sus implicaciones terapéuticas. Med. Leg. Costa Rica. 2018 [citado 22/06/2022];35(1):3-10. Disponible en: https://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-00152018000100003&lng=en&nrm=iso&tlng=es
8. Pasqua AV, Mazza OM. Adenocarcinoma ductal de páncreas. Soplan vientos de cambio. Acta Gastroenterol Latinoam. 2022 [citado 20/06/2022]; 52(1):15-7. Disponible en: https://actaojs.org.ar/ojs/index.php/acta/article/view/163
9. Goggins M, Overbeek KA, Brand R, Syngal S, Del Chia¬ro M, Bartsch D, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2019 [citado 20/06/2022];69(1):7-17. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295005/
10. Kohan G, Moro M, Pasqua A, Volpacchio M, Marcaccio F, Kujaruk M. Recomendaciones para el diagnóstico y tratamiento del adenocarcinoma ductal de páncreas. Club del Páncreas de la República Argentina. Acta Gastroenterol Latinoam. 2020 [citado 20/06/2022];50(2). Disponible en: https://www.redalyc.org/journal/1993/199368570001/199368570001.pdf
11. Cuba. Ministerio de Salud Pública. Anuario Estadístico de Salud 2020. La Habana: MINSAP; 2021 [citado 20/06/2022]. Disponible en:
https://salud.msp.gob.cu/disponible-edicion-49-del-anuario-estadistico-de-salud/
12. Sánchez Morales GE, Moguel Valladares RA, Flores Maza J, Clemente Gutiérrez U, Sánchez-García Ramos E, Domínguez Rosado I, et al. Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Rev Gastroenterol México. 2021 [citado 28/06/2022];86:118-24. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32616358/
13. Medina Pérez VM, Fonseca Labrada A, Alsina Tul LE, Lamadrid García J, Carvajal Aballe ML, Fong Baltar ÁL, et al. Caracterización de pacientes con adenocarcinoma de páncreas. Rev. cuban. oncol. 2020 [citado 08/06/2022];18(2):35. Disponible en: http://revoncologia.sld.cu/index.php/onc/article/view/35/29
14. Montejo Gañán I, Ángel Ríos LF, Sarría Octavio de Toledo L, Martínez Mombila ME, Ros Mendoza LH. Estadificación mediante tomografía computarizada del carcinoma de páncreas. Radiol. 2018 [citado 08/06/2022];60(1):10-23. Disponible en: https://www.webcir.org/revistavirtual/articulos/2019/1_marzo/esp/estadificacion_esp.pdf
15. Alarcón Hermoza AM. Cáncer de páncreas, un enemigo de acción silente y rápida y una limitación para la esperanza de vida. Rev. Méd. Urug. 2021 [citado 20/06/2022]; 37(1): e37115. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-03902021000102901
Published
How to Cite
Issue
Section
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
Guidelines for authors
